Iteos Therapeutics Inc (ITOS)

$17.26

+0.55

(+3.29%)▲

Live

Performance

  • $16.73
    $17.41
    $17.26
    downward going graph

    3.07%

    Downside

    Day's Volatility :3.91%

    Upside

    0.86%

    downward going graph
  • $8.20
    $18.75
    $17.26
    downward going graph

    52.49%

    Downside

    52 Weeks Volatility :56.27%

    Upside

    7.95%

    downward going graph

Returns

PeriodIteos Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
54.72%
6.5%
0.0%
6 Months
61.45%
7.1%
0.0%
1 Year
16.28%
9.8%
0.0%
3 Years
-31.6%
14.2%
-20.2%

Highlights

Market Capitalization
592.8M
Book Value
$15.1
Earnings Per Share (EPS)
-3.78
Wall Street Target Price
37.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-15.59%
Return On Equity TTM
-22.67%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
267.6M
EBITDA
-168.4M
Diluted Eps TTM
-3.78
Quarterly Earnings Growth YOY
-0.89
EPS Estimate Current Year
-4.23
EPS Estimate Next Year
-5.1
EPS Estimate Current Quarter
-1.26
EPS Estimate Next Quarter
-1.24

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Iteos Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 117.27%

Current $17.26
Target $37.50

Technicals Summary

Sell

Neutral

Buy

Iteos Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Iteos Therapeutics Inc
Iteos Therapeutics Inc
11.1%
61.45%
16.28%
-31.6%
-12.28%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Iteos Therapeutics Inc
Iteos Therapeutics Inc
39.55
NA
NA
-4.23
-0.23
-0.16
NA
15.1
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Iteos Therapeutics Inc
Iteos Therapeutics Inc
Buy
$592.8M
-12.28%
39.55
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Iteos Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 53.90M → -11.30M (in $), with an average decrease of 133.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -30.55M → -38.21M (in $), with an average decrease of 25.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 45.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 218.1%

Institutional Holdings

  • RA Capital Management, LLC

    12.28%

  • BlackRock Inc

    11.44%

  • Mpm Asset Management, LLC

    7.62%

  • EcoR1 Capital, LLC

    5.56%

  • Boxer Capital LLC

    5.02%

  • MPM Oncology Impact Management LP

    4.85%

Company Information

starting operations in 2012, iteos therapeutics is a clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by developing immunotherapies by design. iteos is developing eos200271, a clinical-stage potent and selective ido1 inhibitor with exceptional brain penetration. the company is also advancing eos100850, an insurmountable and non-brain penetrant adenosine a2a receptor antagonist, into a phase 1 trial in the second half of 2018; and a human adcc-enabling anti-tigit antibody (eos884448), representing an additional, third clinical entry in 2019. based in gosselies, belgium, iteos therapeutics was founded and supported in part by investments from the ludwig institute cancer research (licr), the walloon region of belgium and the european fund for economic and regional development (feder). for more information, please visit www.iteostherapeutics.com.

Organization
Iteos Therapeutics Inc
Employees
157
CEO
Dr. Michel Detheux Ph.D.
Industry
Health Technology

Discover More

FAQs